625095-61-6,MFCD08435984
Catalog No.:AA01EOE2

625095-61-6 | Pradefovir mesylate

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
1 week  
$301.00   $211.00
- +
5mg
1 week  
$578.00   $404.00
- +
10mg
1 week  
$826.00   $578.00
- +
25mg
1 week  
$1,269.00   $888.00
- +
50mg
1 week  
$1,692.00   $1,184.00
- +
100mg
1 week  
$2,252.00   $1,576.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA01EOE2
Chemical Name:
Pradefovir mesylate
CAS Number:
625095-61-6
Molecular Formula:
C18H23ClN5O7PS
Molecular Weight:
519.8963
MDL Number:
MFCD08435984
SMILES:
CS(=O)(=O)O.Clc1cccc(c1)[C@@H]1CCO[P@@](=O)(O1)COCCn1cnc2c1ncnc2N
Properties
Computed Properties
 
Complexity:
668  
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
11  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0  
Rotatable Bond Count:
6  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  

Literature

Title: Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.

Journal: Journal of medicinal chemistry 20080214

Title: Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.

Journal: Current opinion in investigational drugs (London, England : 2000) 20070801

Title: Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.

Journal: Antimicrobial agents and chemotherapy 20060901

Title: HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver.

Journal: Current opinion in investigational drugs (London, England : 2000) 20060201

Title: Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir.

Journal: Journal of clinical pharmacology 20051101

Title: Liver-targeted drug delivery using HepDirect prodrugs.

Journal: The Journal of pharmacology and experimental therapeutics 20050201

Title: Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys.

Journal: Antiviral chemistry & chemotherapy 20041101

Title: Lin CC, et al. Metabolic activation of Pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 625095-61-6
Historical Records
Tags:625095-61-6 Molecular Formula|625095-61-6 MDL|625095-61-6 SMILES|625095-61-6 Pradefovir mesylate
Catalog No.: AA01EOE2
625095-61-6,MFCD08435984
625095-61-6 | Pradefovir mesylate
Pack Size: 1mg
Purity:
1 week
$301.00 $211.00
Pack Size: 5mg
Purity:
1 week
$578.00 $404.00
Pack Size: 10mg
Purity:
1 week
$826.00 $578.00
Pack Size: 25mg
Purity:
1 week
$1,269.00 $888.00
Pack Size: 50mg
Purity:
1 week
$1,692.00 $1,184.00
Pack Size: 100mg
Purity:
1 week
$2,252.00 $1,576.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA01EOE2
Chemical Name: Pradefovir mesylate
CAS Number: 625095-61-6
Molecular Formula: C18H23ClN5O7PS
Molecular Weight: 519.8963
MDL Number: MFCD08435984
SMILES: CS(=O)(=O)O.Clc1cccc(c1)[C@@H]1CCO[P@@](=O)(O1)COCCn1cnc2c1ncnc2N
Properties
Complexity: 668  
Covalently-Bonded Unit Count: 2  
Defined Atom Stereocenter Count: 2  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 33  
Hydrogen Bond Acceptor Count: 11  
Hydrogen Bond Donor Count: 2  
Isotope Atom Count: 0  
Rotatable Bond Count: 6  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
Literature fold

Title: Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.

Journal: Journal of medicinal chemistry20080214

Title: Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.

Journal: Current opinion in investigational drugs (London, England : 2000)20070801

Title: Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.

Journal: Antimicrobial agents and chemotherapy20060901

Title: HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver.

Journal: Current opinion in investigational drugs (London, England : 2000)20060201

Title: Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir.

Journal: Journal of clinical pharmacology20051101

Title: Liver-targeted drug delivery using HepDirect prodrugs.

Journal: The Journal of pharmacology and experimental therapeutics20050201

Title: Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys.

Journal: Antiviral chemistry & chemotherapy20041101

Title: Lin CC, et al. Metabolic activation of Pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31.

Building Blocks More >
2102196-57-4
2102196-57-4
FAA1 agonist-1
AA01EOJU | MFCD31619242
1473450-62-2
1473450-62-2
NITD-349
AA01EOP7 | MFCD31630740
337506-43-1
337506-43-1
1-[(2-chloro-5-nitrophenyl)sulfonyl]-2-methyl-1H-benzimidazole
AA01EOX4 | MFCD01173148
1895916-79-6
1895916-79-6
9-[(1-oxooctadecyl)oxy]-octadecanoicacid
AA01EP76
23609-41-8
23609-41-8
N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide,monohydrochloride
AA01EPFX
1821908-49-9
1821908-49-9
2S-amino-N-[[4-(3,5-dimethylphenoxy)-3-methylphenyl]methyl]-propanamide,monohydrochloride
AA01EPLB | MFCD30537226
101365-58-6
101365-58-6
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide,monohydrochloride
AA01EPRR
65641-84-1
65641-84-1
6,7-dihydro-quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione
AA01EQ0J
1184971-51-4
1184971-51-4
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl-4,4,5,5-d4)quinoxalin-6-amine
AA01EQ7K
2092923-21-0
2092923-21-0
VU6008667
AA01EQD0
Submit
© 2017 AA BLOCKS, INC. All rights reserved.